Company Statera Biopharma, Inc.

Equities

STAB

US8575611046

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
0.0007 ^USD	0.00%		0.00%	+16.67%

2023	Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	CI
2023	Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	CI

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Number of employees: 46

USD in Million	2020	Weight	2021	Weight	Delta
Toll-like Receptors 100.0 %	0	100.0 %	1	100.0 %	+465.54%

USD in Million	2020	Weight	2021	Weight	Delta
United States 100.0 %	0	81.2 %	1	100.0 %	+596.47%

Managers	Title	Age	Since
Yakov Kogan FOU	Founder	50	05/03/05
Andrei V. Gudkov FOU	Founder	66	05/03/05
Michael Handley CEO	Chief Executive Officer	52	27/21/27
Christopher Zosh DFI	Director of Finance/CFO	48	01/14/01
Allie Lopez CTO	Chief Tech/Sci/R&D Officer	-	01/20/01
James Mendolera CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Robert W. Buckheit CTO	Chief Tech/Sci/R&D Officer	63	27/21/27
George Wagner LAW	General Counsel	-	-
Curt Dewitz PRN	Corporate Officer/Principal	-	01/20/01
Todd Headley PRN	Corporate Officer/Principal	-	01/21/01

Members of the board	Title	Age	Since
John A. Kallassy BRD	Director/Board Member	59	02/22/02
Uday Saxena BRD	Director/Board Member	66	17/22/17
Michael Handley CEO	Chief Executive Officer	52	27/21/27
C. Satish Chandran BRD	Director/Board Member	68	24/22/24
Selby Blake Hawley BRD	Director/Board Member	59	17/22/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,416,038	71,416,038 ( 100.00 %)	0	100.00 %

Name	Equities	%	Valuation
Tucker Asset Management LLC 0.001400 %	1,000	0.001400 %	1 $
Manulife Investment Management Ltd. 0.000223 %	159	0.000223 %	0 $
AlphaStream Portfolios, Inc. 0.000062 %	44	0.000062 %	0 $

Statera Biopharma, Inc.

4333 Corbett Drive Suite 1082

80525, Fort Collins

+888 613 8802

http://www.staterabiopharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
STATERA BIOPHARMA, INC.	+16.67%	50.81K
MODERNA, INC.	+18.28%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+1.15%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.40%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-21.46%	19.15B
BIO-TECHNE CORPORATION	+4.69%	12.55B
MEDPACE HOLDINGS, INC.	+27.75%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.65%	11.82B

Other Biotechnology & Medical Research